Minerva Neurosciences, Inc. (NERV)
2.38
-0.18
(-7.03%)
USD |
NASDAQ |
Nov 12, 16:00
Minerva Neurosciences Free Cash Flow (Quarterly) : -8.150M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -8.150M |
| June 30, 2026 | -13.34M |
| March 31, 2026 | -5.427M |
| December 31, 2025 | -4.481M |
| September 30, 2025 | -2.916M |
| June 30, 2025 | -2.042M |
| March 31, 2025 | -4.072M |
| December 31, 2024 | -5.167M |
| September 30, 2024 | -4.352M |
| June 30, 2024 | -3.937M |
| March 31, 2024 | -6.094M |
| December 31, 2023 | -5.991M |
| September 30, 2023 | -4.806M |
| June 30, 2023 | -3.872M |
| March 31, 2023 | -0.1154M |
| December 31, 2022 | -4.126M |
| September 30, 2022 | -9.534M |
| June 30, 2022 | -5.193M |
| March 31, 2022 | -5.808M |
| December 31, 2021 | -4.833M |
| September 30, 2021 | -8.627M |
| June 30, 2021 | -5.925M |
| March 31, 2021 | -5.217M |
| December 31, 2020 | -7.159M |
| September 30, 2020 | -9.872M |
| Date | Value |
|---|---|
| June 30, 2020 | -7.589M |
| March 31, 2020 | -9.202M |
| December 31, 2019 | -14.18M |
| September 30, 2019 | -9.521M |
| June 30, 2019 | -10.13M |
| March 31, 2019 | -9.601M |
| December 31, 2018 | -9.800M |
| September 30, 2018 | -9.985M |
| June 30, 2018 | -11.23M |
| March 31, 2018 | -10.93M |
| December 31, 2017 | -8.964M |
| September 30, 2017 | 24.89M |
| June 30, 2017 | -6.844M |
| March 31, 2017 | -6.045M |
| December 31, 2016 | -8.928M |
| September 30, 2016 | -4.656M |
| June 30, 2016 | -6.055M |
| March 31, 2016 | -6.049M |
| December 31, 2015 | -6.603M |
| September 30, 2015 | -5.727M |
| June 30, 2015 | -7.031M |
| March 31, 2015 | -4.909M |
| December 31, 2014 | -5.029M |
| September 30, 2014 | -27.19M |
| June 30, 2014 | -2.544M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Heron Therapeutics, Inc. | -0.896M |
| Tonix Pharmaceuticals Holding Corp. | -39.43M |
| Karyopharm Therapeutics, Inc. | -24.93M |
| Corbus Pharmaceuticals Holdings, Inc. | -21.25M |
| Ocugen, Inc. | -15.89M |